TG 01 - Targovax

Drug Profile

TG 01 - Targovax

Alternative Names: TG01 - Targovax

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Norsk Hydro; Norwegian Radium Hospital
  • Developer Targovax
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants; Ras gene modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 12 Jun 2018 Targovax terminates a phase II trial in Pancreatic cancer (Combination therapy) prior to recruitment due to inadequate trial design
  • 24 May 2018 Targovax completes a phase I/II trial in Pancreatic cancer (Combination therapy, Adjuvant therapy) in United Kingdom and Norway
  • 12 Oct 2017 Efficacy and adverse events data from a phase I/II trial in Pancreatic cancer released by Targovax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top